After painful flop late last year, Allakos reveals new PhIII data and pivots to new indications
Several years after securing $100 million cash in an NEA-led mega round to pursue its lead drug in certain allergic and inflammatory diseases, one-time high flier Allakos is now pivoting its R&D efforts in the candidate to other diseases and another potential candidate.
The California-based allergy and inflammation player reported data from 24 weeks out in the Phase III trial EoDyssey, which was investigating lead drug candidate lirentelimab in patients with confirmed eosinophilic duodenitis — a chronic inflammatory disease characterized by inflammation in the stomach and part of the small intestine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.